vs

Side-by-side financial comparison of NCS Multistage Holdings, Inc. (NCSM) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $50.6M, roughly 1.2× NCS Multistage Holdings, Inc.). NCS Multistage Holdings, Inc. runs the higher net margin — 29.5% vs -92.6%, a 122.1% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 12.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 7.4%).

NCS Multistage Holdings, Inc. is a global oilfield services and energy technology provider specializing in engineered completion systems for onshore and offshore oil and gas production. It offers multistage fracturing tools that optimize well performance, serving major operators across North America, Latin America, the Middle East and Asia-Pacific, focusing on boosting operational efficiency and resource recovery for upstream energy clients.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

NCSM vs RYTM — Head-to-Head

Bigger by revenue
RYTM
RYTM
1.2× larger
RYTM
$60.1M
$50.6M
NCSM
Growing faster (revenue YoY)
RYTM
RYTM
+71.3% gap
RYTM
83.8%
12.5%
NCSM
Higher net margin
NCSM
NCSM
122.1% more per $
NCSM
29.5%
-92.6%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
43.8%
7.4%
NCSM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NCSM
NCSM
RYTM
RYTM
Revenue
$50.6M
$60.1M
Net Profit
$15.0M
$-55.6M
Gross Margin
88.1%
Operating Margin
10.3%
-87.1%
Net Margin
29.5%
-92.6%
Revenue YoY
12.5%
83.8%
Net Profit YoY
331.0%
EPS (diluted)
$5.43
$-0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NCSM
NCSM
RYTM
RYTM
Q1 26
$60.1M
Q4 25
$50.6M
$57.3M
Q3 25
$46.5M
$51.3M
Q2 25
$36.5M
$48.5M
Q1 25
$50.0M
$32.7M
Q4 24
$45.0M
$41.8M
Q3 24
$44.0M
$33.3M
Q2 24
$29.7M
$29.1M
Net Profit
NCSM
NCSM
RYTM
RYTM
Q1 26
$-55.6M
Q4 25
$15.0M
$-47.5M
Q3 25
$3.8M
$-52.9M
Q2 25
$924.0K
$-46.6M
Q1 25
$4.1M
$-49.5M
Q4 24
$3.5M
$-43.3M
Q3 24
$4.1M
$-43.6M
Q2 24
$-3.1M
$-32.3M
Gross Margin
NCSM
NCSM
RYTM
RYTM
Q1 26
88.1%
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Operating Margin
NCSM
NCSM
RYTM
RYTM
Q1 26
-87.1%
Q4 25
10.3%
-82.2%
Q3 25
6.6%
-102.6%
Q2 25
-5.6%
-93.4%
Q1 25
8.6%
-143.7%
Q4 24
6.5%
-98.6%
Q3 24
6.9%
-132.0%
Q2 24
-14.0%
-139.2%
Net Margin
NCSM
NCSM
RYTM
RYTM
Q1 26
-92.6%
Q4 25
29.5%
-83.0%
Q3 25
8.2%
-103.1%
Q2 25
2.5%
-96.1%
Q1 25
8.1%
-151.4%
Q4 24
7.7%
-103.6%
Q3 24
9.4%
-131.2%
Q2 24
-10.4%
-110.9%
EPS (diluted)
NCSM
NCSM
RYTM
RYTM
Q1 26
$-0.83
Q4 25
$5.43
$-0.73
Q3 25
$1.37
$-0.82
Q2 25
$0.34
$-0.75
Q1 25
$1.51
$-0.81
Q4 24
$1.34
$-0.71
Q3 24
$1.60
$-0.73
Q2 24
$-1.21
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NCSM
NCSM
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$36.7M
$340.6M
Total DebtLower is stronger
$5.3M
Stockholders' EquityBook value
$126.2M
$122.9M
Total Assets
$181.2M
$442.3M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NCSM
NCSM
RYTM
RYTM
Q1 26
$340.6M
Q4 25
$36.7M
$388.9M
Q3 25
$25.3M
$416.1M
Q2 25
$25.4M
$291.0M
Q1 25
$23.0M
$314.5M
Q4 24
$25.9M
$320.6M
Q3 24
$15.3M
$298.4M
Q2 24
$18.6M
$319.1M
Total Debt
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
$5.3M
Q3 25
$5.1M
Q2 25
$5.5M
Q1 25
$5.4M
Q4 24
$6.0M
Q3 24
$6.5M
Q2 24
$6.8M
Stockholders' Equity
NCSM
NCSM
RYTM
RYTM
Q1 26
$122.9M
Q4 25
$126.2M
$139.1M
Q3 25
$110.1M
$148.8M
Q2 25
$106.4M
$-11.9M
Q1 25
$103.2M
$18.9M
Q4 24
$98.8M
$21.7M
Q3 24
$96.0M
$11.2M
Q2 24
$91.0M
$39.3M
Total Assets
NCSM
NCSM
RYTM
RYTM
Q1 26
$442.3M
Q4 25
$181.2M
$480.2M
Q3 25
$162.0M
$506.9M
Q2 25
$158.0M
$372.7M
Q1 25
$155.1M
$386.7M
Q4 24
$152.8M
$392.3M
Q3 24
$145.8M
$363.6M
Q2 24
$139.4M
$381.8M
Debt / Equity
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
0.04×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.06×
Q3 24
0.07×
Q2 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NCSM
NCSM
RYTM
RYTM
Operating Cash FlowLast quarter
$13.1M
Free Cash FlowOCF − Capex
$12.9M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$21.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
$13.1M
$-25.4M
Q3 25
$7.2M
$-26.6M
Q2 25
$3.5M
$-23.3M
Q1 25
$-1.6M
$-40.4M
Q4 24
$10.6M
$-18.8M
Q3 24
$-2.0M
$-25.2M
Q2 24
$6.0M
$-29.1M
Free Cash Flow
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
$12.9M
Q3 25
$6.9M
Q2 25
$3.2M
Q1 25
$-2.1M
Q4 24
$10.4M
Q3 24
$-2.5M
Q2 24
$5.6M
FCF Margin
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
25.5%
Q3 25
14.9%
Q2 25
8.9%
Q1 25
-4.2%
Q4 24
23.1%
Q3 24
-5.6%
Q2 24
19.0%
Capex Intensity
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
0.4%
Q3 25
0.5%
Q2 25
0.8%
Q1 25
0.9%
Q4 24
0.5%
Q3 24
1.0%
Q2 24
1.1%
Cash Conversion
NCSM
NCSM
RYTM
RYTM
Q1 26
Q4 25
0.88×
Q3 25
1.88×
Q2 25
3.81×
Q1 25
-0.41×
Q4 24
3.07×
Q3 24
-0.49×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NCSM
NCSM

Products$33.8M67%
Services$16.8M33%

RYTM
RYTM

Segment breakdown not available.

Related Comparisons